Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation

Hematology Journal

Volumn 5, Issue 1, 2004, Pages 24-31

  Picardi, Alessandra ^a   de Fabritiis, Paolo ^a   Cudillo, Laura ^a   Dentamaro, Teresa ^a   Cupelli, Luca ^a   Ballatore, Giovanna ^a   Venditti, Adriano ^a   Caravita, Tommaso ^a   Cox, Maria Cristina ^a   Catalano, Gianfranco ^a   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Allogeneic stem cell transplantation; Hematological malignant disease; RIC

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FATALITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION COMPLICATION; LONG TERM CARE; MALE; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; REFRACTORY ANEMIA;

ADULT; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 10744232228     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200357     Document Type: Article

References (36)

1. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Result of the 1988-1990 survey. Ann Intern Med 1992; 116: 505-512.
2. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
3. Ueno NT, Rondon G, Mirza MQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
4. Childs R, Chernoff A, Contentin N, Bacheci E, Schurmp D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
5. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vagelzang NJ. Allogeneic stem cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-2024.
6. Thomas ED. Stem cell transplantation: past, present and future. Arch Immunol Ther Exp (Warsz) 1997; 45: 1-5.
7. Thomas ED. A history of hematopoietic cell transplantation. Br J Haematol 1999; 105: 330-339.
8. Giralt S, Estey E, Albitar M, van Besien K Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
9. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant hematologic diseases. Blood 1998; 91: 756-763.
10. Prigozhina TB, Gurevitich O, Zhu J, Slavin S. Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic issues. Transplantation 1997; 63: 1394-1399.
11. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose toxicity therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
12. Khoury FI, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
13. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
14. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T cell depletion. Ann Intern Med 1998; 108: 806-814.
15. Kolb HJ, Schattenberg A, Goldman JM, Herterstein B, Jacobsen N, Arcese W et al. Graft-vs- leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
16. Cullis JO, Jiang YZ, Schwarer AP, Huges TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379-1381.
17. Collins JR RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
18. Slavin S, Naparstek E, Nagler A Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
19. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy. Curr Opin Onc 1999; 11: 87-95.
20. Barret J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111: 6-17.
21. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
22. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000; 85: 304-313.
23. Bader P, Holle W, Klingenbiel T, Handgretinger R, Niethammer D, Beck J. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after BMT. Anticancer Res 1996; 16: 1759-1764.
24. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestation of graft versus host disease in human recipients of marrow from an HLA-matched sibling donors. Transplantation 1974; 18: 296-304.
25. Gooley TA, Leisenring W, Crowley J and Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 1999; 18: 695-706.
26. Bacigalupo A. Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of workshop of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2000; 25: 803-805.
27. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999; 27: 1477-1486.
28. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998; 29: 301-313.
29. Nagler A, Slaavin S, Varadi G, Naparsteck E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
30. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615-620.
31. Wasch R, Reisser S, Hahn H, Bertz H, Enghelardt M, Kunzmann R et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243-250.
32. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leucemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
33. Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Mordini M, Berisso G et al. Reduced intensity thiotepacyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109: 716-721.
34. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant 2001; 7: 473-485.
35. Schetelig J, Kroger N, Held TK, Thielde C, Krus A, Zabelina T et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002; 87: 299-305.
36. Mothy M, Faucher C, Stoppa AM, Viret F, Chabbert I, Chabannon C et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-255.